المؤلفون: James, N. D., Ingleby, F. C., Clarke, Noel W, Amos, C., Attard, G., Brawley, C. D., Chowdhury, S., Cross, W., Dearnaley, D. P., Gilbert, D. C., Gillessen, S., Jones, R. J., Langley, R. E., Macnair, A., Malik, Z. I., Mason, M. D., Matheson, D. J., Millman, R., Parker, C. C., Rush, H. L., Russell, J. M., Au, C., Ritchie, A. W. S., Mestre, R. P., Ahmed, I., Birtle, A. J., Brock, S. J., Das, P., Ford, V. A., Gray, E. K., Hughes, R. J., Manetta, C. B., McLaren, D. B., Nikapota, A. D., O'Sullivan, J. M., Perna, C., Peedell, C., Protheroe, A. S., Sundar, S., Tanguay, J. S., Tolan, S. P., Wagstaff, J., Wallace, J. B., Wylie, James P, Zarkar, A., Parmar, M. K. B., Sydes, M. R.

المساهمون: The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK

Relation: https://dx.doi.org/10.1093/jncics/pkac043; James ND, Ingleby FC, Clarke NW, Amos C, Attard G, Brawley CD, et al. Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI cancer spectrum. 2022 Jul 25;6(4). PubMed PMID: 35877084. Epub 2022/07/26. eng.; http://hdl.handle.net/10541/625446; JNCI Cancer Spectrum

الاتاحة: http://hdl.handle.net/10541/625446
https://doi.org/10.1093/jncics/pkac043

المؤلفون: James, N. D., Ingleby, F. C., Clarke, N. W., Amos, C. L., Attard, G., Brawley, C. D., Chowdhury, S., Cross, W., Dearnaley, D. P., Gilbert, D. C., Gillessen, S., Jones, R. J., Langley, R. E., Macnair, A., Malik, Z. I., Mason, M. D., Matheson, D. J., Millman, R., Parker, C. C., Rush, H. L., Russell, J. M., Au, C., Ritchie, A. W. S., Mestre, R. P., Ahmed, I., Birtle, A. J., Brock, S. J., Das, P., Ford, V. A., Gray, E. K., Hughes, R. J., Manetta, C. B., McLaren, D. B., Nikapota, A. D., O'Sullivan, J. M., Perna, C., Peedell, C., Protheroe, A. S., Sundar, S., Tanguay, J. S., Tolan, S. P., Wagstaff, J., Wallace, J. B., Wylie, J. P., Zarkar, A., Parmar, M. K. B., Sydes, M. R.

مصطلحات موضوعية: Androgen Antagonists/therapeutic use, Androgens, Docetaxel/therapeutic use, Humans, Male, Prostate-Specific Antigen, Prostatic Neoplasms/drug therapy

Relation: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35877084/; JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac043. doi:10.1093/jncics/pkac043.; https://rde.dspace-express.com/handle/11287/622627; JNCI cancer spectrum; PMC9338456

الاتاحة: https://doi.org/10.1093/jncics/pkac043
https://rde.dspace-express.com/handle/11287/622627

المؤلفون: James, N. D., Ingleby, F. C., Clarke, N. W., Amos, C. L., Attard, G., Brawley, C. D., Chowdhury, S., Cross, W., Dearnaley, D. P., Gilbert, D. C., Gillessen, S., Jones, R. J., Langley, R. E., Macnair, A., Malik, Z. I., Mason, M. D., Matheson, D. J., Millman, R., Parker, C. C., Rush, H. L., Russell, J. M., Au, C., Ritchie, A. W. S., Mestre, R. P., Ahmed, I., Birtle, A. J., Brock, S. J., Das, P., Ford, V. A., Gray, E. K., Hughes, R. J., Manetta, C. B., McLaren, D. B., Nikapota, A. D., O'Sullivan, J. M., Perna, C., Peedell, C., Protheroe, A. S., Sundar, S., Tanguay, J. S., Tolan, S. P., Wagstaff, J., Wallace, J. B., Wylie, J. P., Zarkar, A., Parmar, M. K. B., Sydes, M. R.

مصطلحات موضوعية: Androgen Antagonists/therapeutic use, Androgens, Docetaxel/therapeutic use, Humans, Male, Prostate-Specific Antigen, Prostatic Neoplasms/drug therapy

Relation: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35877084/; JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac043. doi:10.1093/jncics/pkac043.; JNCI cancer spectrum; PMC9338456; https://hdl.handle.net/11287/622627

الاتاحة: https://hdl.handle.net/11287/622627
https://doi.org/10.1093/jncics/pkac043